Routine compliance certificate on share dematerialisation for Q2 FY27

Compliance View source PDF Explain this filing

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.7%Reaction day

₹364.00

prior close

₹357.65

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-1.5% vs market

Pharmaceuticals peers, median of 170sector-0.3%-1.4% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.7-0.2-1.5-0.3-1.4

Next day

-4.3-3.0-1.3-2.7-1.5

-5.1-2.7-2.3-2.7-2.4

-5.2-1.9-3.3-2.6-2.6

-3.7-1.7-2.0-3.0-0.7

-1.1-1.0-0.1-3.0+1.9

-0.8-2.0+1.2-3.5+2.7

15d

-10.7-6.6-4.0-3.4-7.3

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Panacea Biotec has submitted a certificate from its registrar Skyline Financial Services, confirming compliance with SEBI Regulation 74(5) for the quarter ended September 30, 2026. The certificate confirms that physical share certificates received for dematerialisation were listed on the stock exchange and cancelled within 15 days, with the depository recorded as the new owner. This is a standard quarterly procedural filing with no financial impact.

Likely market impact

Routine procedural compliance. No material impact on shareholders or stock price.